ESPERITE N.V. (ESP) publishes its half-year report. Revenues, results and consolidated equity were impacted by adverse market conditions on the stem cell business.

CEO, Frédéric Amar, has converted part of his loan notes into 2.5 million shares to support the business and L1 Capital has continued financing the Company.

Amsterdam, The Netherlands – 30 June 2019
read more

ESPERITE (ESP) : L1 Capital subscribes to the 18th tranche of investment today

Amsterdam, The Netherlands – 17 May 2018
read more

ESPERITE (ESP) : L1 Capital subscribes to the 16th tranche of investment today

Amsterdam, The Netherlands – 2 March 2018

read more

ESPERITE (ESP) : L1 Capital subscribes to the 14th tranche of investment today

Amsterdam, The Netherlands – 31 January 2018

read more

ESPERITE (ESP) : L1 Capital subscribes to the 13th tranche of investment today

Amsterdam, The Netherlands – 16 January 2018

read more

ESPERITE (ESP) : L1 Capital subscribes to the 12th tranche of investment today

Amsterdam, The Netherlands – 10 January 2018

read more

ESPERITE (ESP) : L1 Capital invests for total EUR 500K today by subscribing to the Tenth tranche (EUR 250K) and shows confidence by investing additionally EUR 250K under the same conditions.

Amsterdam, The Netherlands – 9 November 2017

read more

ESPERITE (ESP) : L1 Capital subscribes to the Ninth tranche of investment today

Amsterdam, The Netherlands – 30 October 2017

read more

ESPERITE (ESP) : EUR 1.1 million of new funding provided by L1 Capital to support Esperite’s strategy, commercial activities and development of innovative technologies

Amsterdam, The Netherlands – 10 October 2017

read more

ESPERITE (ESP): L1 Capital subscribes to the Seventh tranche of investment today

Zutphen, The Netherlands, 31 August 2017

read more